The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study.
The aim of this case-control study was to investigate the potential role of the A-2518G polymorphism of the gene of monocyte chemoattractant protein 1 (MCP-1, a cytokine playing an important role in innate immunity) in conferring susceptibility to mood disorders. The sample studied included 96 outpatients with DSM-IV-TR diagnosis of major depressive disorder, bipolar disorder I (BD I) or BD II and 161 matched healthy controls. All subjects were genotyped for the A-2518G polymorphism of the MCP-1 gene. Genotypic and allelic associations were explored between patients and controls and across the different diagnostic groups (chi(2) tests). No genotypic (chi(2) = 8.215, d.f. = 6, p = 0.223) or allelic (chi(2) = 5.058, d.f. = 3, p = 0.168) association for the A-2518G polymorphism of SCYA2 was found considering cases and controls. Nevertheless, important correlations were observed when patients were divided into diagnostic subgroups. A significantly higher frequency of the AA genotype (chi(2) = 7.233, d.f. = 2, p = 0.027) and of the A allele (chi(2) = 4.730, d.f. = 1, p = 0.030) was observed in subjects with BD. In addition, independently from diagnosis, a higher number of lifetime suicide attempts was found in subjects with the AA genotype of the A-2518G polymorphism of the MCP-1 gene (F = 3.802, p = 0.026). The present preliminary results, though limited by the relatively small sample, suggest a possible role of the SCYA2 in conferring susceptibility to BD and, if confirmed, may represent a biological discriminative influence between mood disorder subtypes.
Altamura
A Carlo
AC
Department of Psychiatry, Geriatric Medicine Unit, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy.
Mundo
Emanuela
E
Cattaneo
Elisabetta
E
Pozzoli
Sara
S
Dell'osso
Bernardo
B
Gennarelli
Massimo
M
Vergani
Carlo
C
Trabattoni
Daria
D
Arosio
Beatrice
B
Clerici
Mario
M
D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology; D001923:Brain Chemistry / Q000235:genetics* / Q000276:immunology; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000235:genetics*; D004252:DNA Mutational Analysis; D003865:Major Depressive Disorder / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D005260:Female; D005787:Gene Frequency / Q000235:genetics / Q000276:immunology; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000235:genetics* / Q000276:immunology / Q000503:physiopathology; D011110:Polymorphism, Genetic / Q000235:genetics*; D013406:Suicide, Attempted
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D005819:Genetic Markers